Cannasouth is a Biopharmaceutical Research and Development company based at Waikato Innovation Park, Ruakura. Cannasouth has been established to focus on the commercial development of medically beneficial attributes of Cannabinoids, such as CBD and associated chemical structures that are produced by the plant. In Jan 2017 along with Callaghan Innovation, AGMARDT and Waikato University, Cannasouth conducted one of the first Ministry of Health approved Supercritical Co2 extraction - HPLC characterisation, extraction and fractionation of CBD (Cannabidiol) from New Zealand providence Industrial Hemp sourced from our research and cultivar breeding program. Cannasouth is presently commissioning a GMP – ISO certified Bio-pharmaceutical research laboratory based at Ruakura and facilitating a 3 year PhD Cannabinoid Science study based within our new facility.



Gallagher Core Facilities Building,
Waikato Innovation Park,
1 Melody Lane,
Hamilton East,
New Zealand

+64 (0)7 949 8393


Cannasouth Initial Public Offering (IPO) passes minimum subscription level of $5m

Cannasouth is seeking to raise a minimum of $5 million (10 million new ordinary shares) and a maximum of $10 million (20 million new ordinary shares) in the IPO.
Released Jun. 06th, 2019

UPLOAD NEW PRESS RELEASE (log in required)

Log in to upload press releases


If you have any questions about CannaSouth or any of their products, please post them here.

0 Questions